Belotero Balance (+) Lidocaine Dermal Filler
Merz North America, Inc. · Decision date Oct 24, 2025
What did the FDA decide?
FDA records P090016/S068 as a supplement to PMA P090016, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 24, 2025.
FDA approval order statement
modifications to the assay for determining the concentration of lidocaine hydrochloride and its impurities.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 24, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P090016/S068
- Regulatory pathway
- PMA supplement
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- Decision code
- OK30
- Decision date
- Oct 24, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P090016/S068 received
Application receipt date recorded by FDA.
P090016/S066 · Related supplement
Belotero Balance (+) Lidocaine Dermal Filler
P090016/S068 · FDA decision
30-Day Notice
P090016/S067 · Related supplement
Belotero Balance Dermal Filler; Belotero Balance (+) Lidocaine
Timeline entries are records held by MedtechLedger for P090016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P090016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Belotero Balance (+) Lidocaine Dermal FillerP090016/S066 | Merz North America, Inc. | PMA supplement | Oct 10, 2025 | FDA |
| Merz North America, Inc. | PMA supplement | May 3, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Merz North America, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4133 Ct.ney Rd., Suite 10, Franksville, WI, 53126
Sources and methodology
- Original FDA record: P090016/S068
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




